

MR and PET in stroke: Heiss and Weber provide an overview of the complementarity and current state of the art of PET and MR imaging in differentiating irreversible tissue damage and critically hypoperfused but potentially salvageable tissue in stroke patients. *Page 187*

PET lung image quantification: Chen and colleagues provide an educational overview of data evaluating ^{18}F -FDG PET quantification approaches in lung diseases, focusing on methods to account for variations in lung components and interpretation of derived parameters. *Page 194*

Commentary on SSTR antagonists: Hicks offers perspective on efforts to extend peptide receptor radionuclide therapy targeting the somatostatin receptor beyond neuroendocrine tumors and previews an article on this topic in this issue of *JNM*. *Page 196*

MTV in lymphoma: Gallamini and Kostakoglu preview an article in this issue of *JNM* on the prognostic value of total metabolic tumor volume calculated by adaptive thresholding and emphasize the need for validated cutoff values in clinical practice. *Page 198*

“Small data” innovation: Kesner and Weber argue for a paradigm shift in image data-saving practice toward more robust access and archiving, as a low-cost resource for innovation through informative details inherent within data or datasets. *Page 201*

FETrp and AMT PET in PDX models: Michelaugh and colleagues test *in vivo* uptake and kinetics of the novel tracer ^{18}F -FETrp in patient-derived xenograft mouse models and compare them with ^{11}C -AMT uptake to assess tryptophan metabolism. *Page 208*

Imaging asparaginase biodistribution: van der Meer and colleagues explore the *in vivo* biodistribution of a radiolabeled version of the antileukemic drug asparaginase and provide evidence for tissue-specific clearance mechanisms that may affect the drug’s action. *Page 214*

Oncolytic virus therapy: Wang and colleagues develop viral-based platforms with 2 specific gene reporters, human sodium iodide symporter and human somatostatin receptor 2, in the vaccinia-based oncolytic virus and test viral constructs for tracking and treating tumor development *in vivo*. *Page 221*

^{68}Ga -BBN-RGD PET: Zhang and colleagues report on first-in-human safety and efficacy PET studies with a ^{68}Ga -labeled heterodimeric peptide bombesin-RGD that targets both integrin $\alpha_3\beta_3$ and gastrin-releasing peptide receptors. *Page 228*

$^{99\text{m}}\text{Tc}$ -PSMA-I&S for radiosurgery: Robu and colleagues describe development and initial animal and human biodistribution studies with this cost-effective kit for intraoperative prostate-specific membrane antigen targeting of small metastatic soft tissue lesions. *Page 235*

Detecting ovarian sentinel nodes: Speth and colleagues report on a feasibility study comparing detection of sentinel nodes during surgery and on postresection SPECT/CT in patients with ovarian or endometrial cancer. *Page 243*

Intraoperative fluorescence tumor imaging: Moore and colleagues assess the potential for repurposed intraoperative open-field imaging devices not specifically paired with an imaging agent to guide surgical management of solid tumors. *Page 246*

Age and PET breast cancer staging: Lebon and colleagues compare rates of distant breast cancer metastasis on initial ^{18}F -FDG PET/CT imaging in patients younger and older than 40 years. *Page 252*

TERT mutation in thyroid cancer: Yang and colleagues examine the status of the telomerase reverse transcriptase promoter mutation in distant metastatic differentiated thyroid cancer and evaluate correlations among mutations, radioiodine uptake, and therapy response. *Page 258*

Predicting esophageal pathologic response: Findlay and colleagues reevaluate current PET metabolic response assessment parameters for neoadjuvant chemotherapy in esophageal cancer and look at the potential utility of metabolic nodal stage and nodal response parameters. *Page 266*

TMTV measurement in lymphoma: Cottereau and colleagues compare the prognostic value of baseline total metabolic tumor volumes measured on ^{18}F -FDG PET/CT with adaptive thresholding methods or fixed SUV_{max} thresholds in patients with peripheral T cell lymphoma. *Page 276*

CT density in PET-based LN staging: Giesel and colleagues explore correlations between SUV_{max} from PET and semiautomated CT density measurements in PET/CT differentiation of benign from malignant lymph nodes in various cancers. *Page 282*

NAMPT inhibition and NETs: Elf and colleagues evaluate the potential of radiosensitizing effects from inhibition of nicotinamide phosphoribosyltransferase in ^{177}Lu -DOTATATE treatment in a neuroendocrine tumor model. *Page 288*

GRPR radioligand for theranostics: Dalm and colleagues report on the results of a preclinical study exploring the use of the gastrin-releasing peptide receptor antagonist NeoBOMB1 for theranostic applications by determining the biodistribution of ^{68}Ga -NeoBOMB1 and ^{177}Lu -NeoBOMB1. *Page 293*

New tumor targets with sst_2 antagonist: Reubi and colleagues quantitatively compare ^{125}I -JR11 sst_2 antagonist binding *in vitro* with that of the sst_2 agonist ^{125}I -Tyr 3 -octreotide in a variety of neuroendocrine and nonneuroendocrine tumors. *Page 300*

^{68}Ga -DOTATATE PET/CT interobserver agreement: Fendler and colleagues explore interpretation agreement between high- and low-experience observers in ^{68}Ga -DOTATATE PET/CT imaging of 50 patients with neuroendocrine tumors. *Page 307*

Response predictors for ^{177}Lu -PSMA therapy: Ferdinandus and colleagues investigate the effects of different pretherapeutic parameters on therapeutic response with this prostate-specific membrane antigen in men with metastatic prostate cancer. *Page 312*

^{11}C -ER176 specific binding: Ikawa and colleagues determine in healthy volunteers whether the sensitivity of ^{11}C -ER176, a translocator protein radioligand, is similar to the low sensitivity noted *in vitro* and assess the binding potential of ^{11}C -ER176 in the human brain. *Page 320*

^{11}C -HED PET and denervation in PD: Wong and colleagues describe the results of a study of regional patterns of cardiac sympathetic denervation in idiopathic Parkinson disease using ^{11}C -hydroxyephedrine PET to determine the denervation rate over 2 years. *Page 326*

^{18}F -AV-1451 kinetics in humans: Baker and colleagues evaluate the *in vivo* kinetics of the novel tau-specific PET radioligand ^{18}F -AV-1451 in cognitively healthy controls and individuals with Alzheimer disease, using reference region analyses. *Page 332*

Cellular dosimetry of ^{64}Cu : Cai and colleagues model the cellular dosimetry of ^{64}Cu under different geometries commonly used to study its cytotoxic effects. *Page 339*

^{211}At -induced systemic effects in mice: Langen and colleagues explore ^{211}At tissue accumulation in targeted α -therapy, including effects on transcriptional regulation in various nonthyroid tissues induced, in part, by thyroid hormone-dependent signaling. *Page 346*